Home > Result Summaries: Compounds > alosetron > Result Summary for S3B20023

Result Summary for S3B20023

Result Summary

Protocol ID:	S3B20023
Clinical Study ID:	S3B20023
Official Title:	A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Phase II Study to Assess the Clinical Efficacy of Alosetron (GR68755) in Male Subjects With Irritable Bowel Syndrome
Phase:	Phase 2
Study Indications or Diseases:	Irritable Colon
Generic Name:	alosetron
Trade/Product Name:	lotronex;lotronex
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Abstract: Gender differences in placebo response in patients with diarrhea-predominant irritable bowel syndrome (d-ibs). Ameen, V. Z. MD, Heath, A. T., and Chang, L. Digestive Disease Week 2005: American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, Society for Surgery of the Alimentary Tract 5/15/2005 Chicago, IL; USA 12-week randomized, double-blind, placebo-controlled, parallel,-group, dose-ranging, Phase II study to assess the clinical efficacy of alosetron in male subjects with IBS, Edwards EB, Heitman CK, Hall P, Hamedani AG, Dukes G, Mangel, Am J Gastro 96(9 supp 1): S317, 2001 Phase II Dose-ranging Study of Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant Irritable Bowel Syndrome, L Chang, V Ameen, G Dukes, D McSorley, E. Carter, E Mayer, Am J Gastro,100:115-123,2005